bioAffinity Technologies Appoints New Board Members to Enhance Diagnostics Expertise

bioAffinity Technologies has appointed Roberto Rios and John J. Oppenheimer to its Board of Directors, enhancing the company's financial and clinical expertise. The appointments aim to bolster the company's growth in diagnostics for lung diseases. The company's stock has a Buy rating with a $6.00 price target and a current market cap of $6.64M.

bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company specializing in noninvasive diagnostics for early detection of lung cancer and other diseases, has appointed two distinguished individuals to its Board of Directors. The appointments of Roberto Rios, CPA, and John J. Oppenheimer, M.D., aim to strengthen the company's financial and clinical expertise, thereby enhancing its growth prospects in diagnostics for lung diseases.

Roberto Rios, a seasoned executive with over four decades of experience in corporate finance and governance, brings a wealth of expertise from various industries including biotechnology, medical devices, and large-scale construction. He has held prominent financial leadership roles at ILEX Oncology, BioMedical Enterprises, and Bartlett Cocke General Contractors, and currently serves on the boards of CCC Group and Stem Cell Reserve. His track record in guiding companies through growth, capital strategy, and operational excellence will significantly bolster bioAffinity Technologies' financial foundation.

John J. Oppenheimer, M.D., is a renowned clinical leader and researcher in the diagnosis and treatment of asthma and COPD. He serves as the Director of Clinical Research at Pulmonary and Allergy Associates and is a Clinical Professor of Medicine at the University of Medicine and Dentistry of New Jersey-Rutgers. With extensive clinical experience, Dr. Oppenheimer has participated in over 180 clinical studies and authored more than 260 publications. His leadership roles with the American Board of Allergy and Immunology, the American Academy of Allergy, Asthma & Immunology, and the American College of Allergy, Asthma & Immunology underscore his expertise in guiding scientific and clinical strategies, particularly in the development of companion diagnostics for the growing asthma therapeutics market, valued at $26 billion.

The appointments come as bioAffinity Technologies seeks to increase sales of its flagship product, CyPath® Lung, and develop new companion diagnostics for asthma and COPD. CyPath® Lung uses advanced flow cytometry and artificial intelligence to identify cell populations in patient sputum that indicate malignancy, with clinical study results demonstrating high sensitivity, specificity, and accuracy in detecting lung cancer.

The company also announced that Gary Rubin stepped down from the Board of Directors for personal reasons, with Maria Zannes, President and CEO, expressing gratitude for his contributions over the past seven years.

The stock of bioAffinity Technologies has a Buy rating with a $6.00 price target and a current market cap of $6.64M. The company's forward-looking statements include potential risks and uncertainties, such as the contributions of the newly appointed directors and the risks outlined in its filings with the SEC.

References:
[1] https://finance.yahoo.com/news/bioaffinity-technologies-appoints-members-board-120000250.html
[2] https://www.stocktitan.net/news/BIAF/bio-affinity-technologies-appoints-new-members-to-board-of-whrunytyh5xb.html